|Calculated MW||29 and 35 kDa, monomer, glycosylated|
|Other Names||Interleukin-29, IL-29, IFN-Lambda 1, Interferon-Lambda 1, Cytokine ZCYTO21, IL29, IFNL1, ZCYTO21.|
|Source||Human 293 cell expressed|
|Assay&Purity||SDS-PAGE; > 95%|
|Results||0.5 to 5 ng/ml|
|Application Notes||Reconstitute in sterile PBS containing 0.1% endotoxin-free recombinant human serum albumin.|
|Storage||-80°C; Lyophilized in PBS.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
IL-29 is distantly related to type I interferons and the IL-10 family. Expression of IL-29 is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor β (IL10RB) and interleukin 28 receptor α. IL-29 exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumor activity. IL-29 acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-29 produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. IFN-Lambda 1 antiviral and antiproliferative activity requires Interferon-Lambda 2 receptor tyrosine residues.
Sheppard P.,et al.Nat. Immunol. 4:63-68(2003).
Kotenko S.V.,et al.Nat. Immunol. 4:69-77(2003).
Li M.,et al.Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
Grimwood J.,et al.Nature 428:529-535(2004).
Donnelly R.P.,et al.J. Interferon Cytokine Res. 30:555-564(2010).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.